Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimavanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 20/20 | 0.88 |
| ▸ | HTR2C | P28335 | 4/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.88 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | GPR183 | P32249 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.88 |
| ▸ | APLNR | P35414 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.88 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimavanserin SCHEMBL971607 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL5503797 | 0.94 | HTR2A (1.00) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL675165 | 0.94 | HTR2A (1.00) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL27676488 | 0.93 | HTR2A (0.88) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL971246 | 0.91 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL20766842 | 0.91 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL20794857 | 0.91 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL970683 | 0.90 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Succinic Acid SCHEMBL28763260 | 0.90 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL1395694 | 0.89 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868176-B2 | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation | ACADIA PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20060111399-A1 | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation | ACADIA PHARMACEUTICALS INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111399-A1 | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation | FH, CPS1, CS | HTR2A 4702/4885HTR2C 4564/4885ABCB11 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.